The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment: A Randomized, Double-Blind, Placebo-Controlled Study

What this Trial Is About

Seasonal allergic rhinitis (AR) is a common chronic nasal condition caused by an overreaction to allergens such as pollen, leading to symptoms like sneezing, a runny nose, itching, and nasal congestion. This condition often affects quality of life by causing fatigue and difficulty concentrating, and it may be linked with asthma in many patients. The study aims to evaluate a humanized antibody targeting the interleukin-4 receptor alpha subunit in people with uncontrolled seasonal allergic rhinitis who are already receiving standard treatment. Participants in this randomized, double-blind, placebo-controlled Phase 2 study will receive either a subcutaneous injection of the interleukin-4 receptor antibody or a placebo injection. The study will compare these treatments in their effect on symptoms of seasonal allergic rhinitis. The treatment period lasts up to 2 weeks, with ongoing monitoring to assess changes in nasal symptoms. Throughout the study, participants will report their nasal symptoms daily, focusing on changes from their baseline condition. Researchers will measure the average change in total nasal symptom scores by week 2 to evaluate the treatment's effects. The study includes safety monitoring and requires participants to provide informed consent. Total participant involvement spans the treatment and observation periods, ensuring thorough assessment of efficacy and safety.

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis